ES8705921A1 - Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes. - Google Patents

Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.

Info

Publication number
ES8705921A1
ES8705921A1 ES553374A ES553374A ES8705921A1 ES 8705921 A1 ES8705921 A1 ES 8705921A1 ES 553374 A ES553374 A ES 553374A ES 553374 A ES553374 A ES 553374A ES 8705921 A1 ES8705921 A1 ES 8705921A1
Authority
ES
Spain
Prior art keywords
production
dna sequences
human
optimal
somatomedin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES553374A
Other languages
English (en)
Other versions
ES553374A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen NV filed Critical Biogen NV
Publication of ES553374A0 publication Critical patent/ES553374A0/es
Publication of ES8705921A1 publication Critical patent/ES8705921A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

PROCEDIMIENTO MODIFICADO PARA PRODUCIR UN POLIPEPTIDO EN UN HOSPEDANTE TRANSFORMADO CON UNA MOLECULA DE ADN RECOMBINANTE. COMPRENDE: A) SUSTITUIR UNA PORCION DEL EXTREMO TERMINAL N DE UNA SECUENCIA DE ADN QUE CODIFICA UN POLIPEPTIDO ANALIZABLE POR UNA SERIE DEGENERADA DE SECUENCIAS DE ADN QUE CODIFICAN UNA PORCION DEL EXTREMO TERMINAL N DEL POLIPEPTIDO DESEADO; B) EXPRESAR EN UN HOSPEDANTE TRANSFORMADO LA SERIE RESULTANTE DE SECUENCIAS DE ADN HIBRIDO; C) SELECCIONAR LAS SECUENCIAS DE ADN QUE PERMITEN LA PRODUCCION OPTIMA DEL POLIMERO ANALIZABLE; Y D) UTILIZAR UNA PORCION DEL EXTREMO TERMINAL N DE LAS SECUENCIAS DE ADN HIBRIDO SELECCIONADO PARA EXPRESAR AL POLIPEPTIDO DESEADO EN EL HOSPEDANTE. EL POLIPEPTIDO ANALIZABLE SE SELECCIONA ENTRE GALACTOOQUINOSA Y D-GALACTOSIDASA; EL POLIPEPTIDO DESEADO SE SELECCIONA ENTRE INTERFERONES, ENZIMAS Y ANTIGENOS VIRALES; LA MOLECULA ADN RECOMBINANTE SE SELECCIONA ENTRE PLC24MUSMC1 A PLC24MUSMC10 Y EL HOSPEDANTE SE SELECCIONA ENTRE CEPAS DE E. COLI, PSEUDOMONAS Y LEVADURAS. SE UTILIZA PARA ESTIMULAR EL CRECIMIENTO DE TEJIDOS EN HERIDAS.
ES553374A 1985-03-26 1986-03-25 Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes. Expired ES8705921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858507833A GB8507833D0 (en) 1985-03-26 1985-03-26 Production of human somatomedin c

Publications (2)

Publication Number Publication Date
ES553374A0 ES553374A0 (es) 1987-05-16
ES8705921A1 true ES8705921A1 (es) 1987-05-16

Family

ID=10576658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES553374A Expired ES8705921A1 (es) 1985-03-26 1986-03-25 Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.

Country Status (14)

Country Link
EP (1) EP0215110B1 (es)
JP (4) JPH0691832B2 (es)
CN (1) CN1034588C (es)
AT (1) ATE87977T1 (es)
AU (1) AU594950B2 (es)
CA (1) CA1339305C (es)
DE (1) DE3688225T2 (es)
DK (1) DK175223B1 (es)
ES (1) ES8705921A1 (es)
GB (1) GB8507833D0 (es)
IL (1) IL78278A0 (es)
NO (1) NO302709B1 (es)
WO (1) WO1986005810A1 (es)
ZA (1) ZA862240B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260149A1 (en) * 1986-09-12 1988-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Human prorelaxin for therapeutic use
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
JP6018719B1 (ja) * 2016-03-15 2016-11-02 Ｂｘ新生精機株式会社 シャッター開閉機の巻上装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
SE8303626D0 (sv) * 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
EP0151760A1 (en) * 1984-01-06 1985-08-21 Takeda Chemical Industries, Ltd. Novel DNA and use thereof
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields

Also Published As

Publication number Publication date
EP0215110A4 (en) 1987-07-09
GB8507833D0 (en) 1985-05-01
DE3688225T2 (de) 1993-07-22
ES553374A0 (es) 1987-05-16
DK175223B1 (da) 2004-07-12
NO864724L (no) 1987-01-23
NO302709B1 (no) 1998-04-14
JPS62502305A (ja) 1987-09-10
JPH07145200A (ja) 1995-06-06
JPH07102152B2 (ja) 1995-11-08
AU5665786A (en) 1986-10-23
ZA862240B (en) 1986-11-26
EP0215110B1 (en) 1993-04-07
ATE87977T1 (de) 1993-04-15
DE3688225D1 (de) 1993-05-13
JP2602628B2 (ja) 1997-04-23
CN86102889A (zh) 1986-11-26
WO1986005810A1 (en) 1986-10-09
DK569886A (da) 1986-11-26
DK569886D0 (da) 1986-11-26
EP0215110A1 (en) 1987-03-25
JP2568383B2 (ja) 1997-01-08
AU594950B2 (en) 1990-03-22
JPH07143885A (ja) 1995-06-06
CA1339305C (en) 1997-08-19
JPH07143896A (ja) 1995-06-06
IL78278A0 (en) 1986-07-31
JPH0691832B2 (ja) 1994-11-16
CN1034588C (zh) 1997-04-16

Similar Documents

Publication Publication Date Title
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
IE820069L (en) Recombinant dna encoding a polypeptide
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
EP0258411A4 (en) DNA ENCODING STREPTAVIDINE, STREPTAVIDINE PRODUCED FROM IT, FUSED POLYPEPTIDES WITH AMINO ACID SEQUENCES FROM STREPTAVIDINE AND USES.
IE832259L (en) Dna sequences swine growth hormone polypeptides
DK568587A (da) Dna fragmenter indeholdende alkalisk cellulasegen, rekombinante plasmider indeholdende disse dna fregmenter og rekombinante mikroorganismer
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
AU1987088A (en) A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
IL88095A0 (en) Dna sequences,proteins and gene preparations
ES8705921A1 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
GB9215232D0 (en) Vaccines
IT8119759A0 (it) Umano, dna e plasmidi che polipeptide prodotto codificano per questa sequenza, microbiologicamente con la sequenza microorganismi che contengono di aminoacidi dell'interferone queste informazioni genetiche e processo per la loro preparazione.
IE831918L (en) Dna sequences, recomninant dna molecules, production of¹bovine growth hormone polypeptides
FI93470B (fi) Menetelmä erytropoietiinin valmistamiseksi ja siinä käytettyjä DNA-sekvenssejä
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: BIOGEN, INC.

FD1A Patent lapsed

Effective date: 20070321